Compare MYPS & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYPS | SER |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 56.4M |
| IPO Year | 2020 | 2024 |
| Metric | MYPS | SER |
|---|---|---|
| Price | $4.22 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 71.0K | 67.3K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $235,097,000.00 | $130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $0.40 | $1.14 |
| 52 Week High | $5.24 | $4.26 |
| Indicator | MYPS | SER |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 43.26 |
| Support Level | $4.21 | $1.59 |
| Resistance Level | $5.10 | $2.13 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 52.45 | 33.33 |
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.